Timing may be everything in post-heart attack lipid management. Current guidelines relegate PCSK9 inhibitors to second- or third-line status after myocardial infarction, meaning many high-risk patients spend weeks or months with dangerously elevated LDL cholesterol during a window when vulnerable plaques and arterial inflammation make recurrent events most likely. The AMUNDSEN trial directly challenges that sequencing convention.
This international, phase 4 randomized controlled trial enrolled 2,161 adults across 48 sites in six countries, all presenting with high-risk acute MI and undergoing percutaneous coronary intervention. Participants were randomized 1:1 to receive evolocumab 140 mg subcutaneously every two weeks for one year — with the critical distinction that the first injection was administered before the balloon inflation — versus standard care with high-intensity oral lipid-lowering therapy alone. The control arm could receive PCSK9 inhibitor therapy if guideline thresholds were subsequently met. The primary composite endpoint assessed LDL reduction below 55 mg/dL combined with at least a 50% relative reduction, alongside one-year clinical outcomes including major adverse cardiovascular events.
The decision to initiate PCSK9 inhibition in the catheterization laboratory — before mechanical reperfusion — represents a meaningful operational shift. Mechanistically, aggressive early LDL lowering may reduce ischemia-reperfusion injury, stabilize residual non-culprit plaques, and dampen systemic inflammatory responses that peak in the acute MI period. This aligns with emerging data suggesting that LDL-lowering speed, not just magnitude, independently influences recurrent event risk.
The trial's phase 4 multicenter design and three-plus-year enrollment window strengthen generalizability, though open-label assignment limits blinding at the prescriber level. Importantly, allowing optional PCSK9 inhibitor use in the control arm adds real-world validity but may compress between-group differences. If clinical outcome benefits emerge — not merely lipid target attainment — this trial could meaningfully reposition PCSK9 inhibitors from rescue therapy to first-line acute intervention, with implications for global cardiology protocols.